FDA approval for Incyte drug could pave way for JAK inhibitors
Incyte (NASDAQ:INCY), a Wilmington, Delaware-based biotechnology company has received approval from the U.S. Food and Drug Administration for its drug Jakafi, the first approved drug to treat myelofibrosis, a bone marrow disease in which bone marrow is replaced with scar or fibrous tissue affecting the production of new blood cells. Although it is characterized as […]